Furthermore, using optical window imaging (18–21) in breast cancer GEMMs, we mapped drug targeting in an AKT hyperactivated setting, demonstrating the utility of the Akt-FRET biosensor mouse in preclinical imaging of targeted therapies in a longitudinal manner (22–24). The gene discussed is AKT1; the disease is breast cancer.